# 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

> **NCT02294227** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 341 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **BIOLOGICAL:** Secukinumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02294227
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-29
- **Primary completion:** 2016-02-16
- **Final completion:** 2017-12-19
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2019-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02294227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02294227, "16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02294227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*